관리-도구

편집 파일: 1602943021.M510681P3098.server.saraya-global.com,S=16656,W=17148:2,

Envelope-to: info@worldwide.saraya.com
Delivery-date: Sat, 17 Oct 2020 21:57:01 +0800
Date: Sat, 17 Oct 2020 15:56:11 +0200
To: info@worldwide.saraya.com
From: PMC Acquisitions + Licensing <info@licensing4pharma.de>
Reply-to: PMC Acquisitions + Licensing <info@licensing4pharma.de>
Message-ID: <68f22e579469b2a097885c44f9ac7b51@www.licensing4pharma.com>
MIME-Version: 1.0
Content-Type: multipart/alternative;
	boundary="b1_68f22e579469b2a097885c44f9ac7b51"
Subject: ***SPAM*** Divestments / Pharma

--b1_68f22e579469b2a097885c44f9ac7b51
Content-Type: text/plain; charset = "iso-8859-1"
Content-Transfer-Encoding: 8bit

To view the message, please use an HTML compatible email viewer!

--b1_68f22e579469b2a097885c44f9ac7b51
Content-Type: text/html; charset = "iso-8859-1"
Content-Transfer-Encoding: 8bit

Please forward to: Managing Director, CEO, Head of Business Development

Dear Madam, Dear Sir,&nbsp;

This is to inform you that we may offer to you the following pharmaceutical businesses &amp; brands to purchase

I. Company Sales:

<table border="0" cellpadding="0" cellspacing="2" style="font-family:arial">
	<tbody>
		<tr>
			<td colspan="2">
			1. Pharmaceutical Company -&nbsp; OTC Brands
			</td>
			<td colspan="2">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2">&nbsp;</td>
			<td colspan="2">&nbsp;</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Type of Business:
			</td>
			<td>Marketing and Sales Company</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Products:&nbsp;
			</td>
			<td>Niche OTC Brands in therapeutic areas of subacute and chronic diseases</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Employees:
			</td>
			<td>ca. 25</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Territory:
			</td>
			<td>
			Germany, Austria, Switzerland
			</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Deal Type:
			</td>
			<td>share deal, equity participation</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Sales:
			</td>
			<td>&gt; 25 m Euro (strong growing)</td>
		</tr>
	</tbody>
</table>

&nbsp;

II. Brand Sales:

<table border="0" cellpadding="0" cellspacing="2" style="font-family:arial">
	<tbody>
		<tr>
			<td colspan="2" style="white-space:nowrap">
			1. Injectable Rx-Brand&nbsp;in Emergency Treatment / Hospitals
			</td>
		</tr>
		<tr>
			<td colspan="2">&nbsp;</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Therapeutic Area:
			</td>
			<td>
			&nbsp;Emergency treatment for use in Hospitals / Niche Indication
			</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Product:
			</td>
			<td>
			Famous Niche Rx Brand, and Phase-III-Project for successor product
			</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Territory:
			</td>
			<td>global</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Deal Type:
			</td>
			<td>Divestment</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Sales:
			</td>
			<td>
			ca. 40 m EUR (growing); sales potential of the Phase-III-Project in the higher 3-digit million EUR range
			</td>
		</tr>
	</tbody>
</table>

&nbsp;

<table border="0" cellpadding="0" cellspacing="2" style="font-family:arial">
	<tbody>
		<tr>
			<td colspan="2" style="white-space:nowrap">
			2. Bundle of Rx-Brands / Inflammatory Diseases and Dermatology
			</td>
		</tr>
		<tr>
			<td colspan="2">&nbsp;</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Therapeutic Area:
			</td>
			<td>
			&nbsp;Acute and chronic Inflammatory Diseases, Dermatology
			</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Product:
			</td>
			<td>Established Brands</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Territory:
			</td>
			<td>mainly Europe (ca. 78% of sales)</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Deal Type:
			</td>
			<td>Divestment</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Sales:
			</td>
			<td>
			ca. 40 m EUR
			</td>
		</tr>
	</tbody>
</table>

&nbsp;

<table border="0" cellpadding="0" cellspacing="2" style="font-family:arial">
	<tbody>
		<tr>
			<td colspan="2" style="white-space:nowrap">
			3. Rx-Brands for the treatment of Respiratory Diseases
			</td>
		</tr>
		<tr>
			<td colspan="2">&nbsp;</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Therapeutic Area:
			</td>
			<td>Acute and chronic pulmonary diseases</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Product:
			</td>
			<td>Established Rx-Brands</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Territory:
			</td>
			<td>Europe, ROW</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Deal Type:
			</td>
			<td>Divestment&nbsp;</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Sales:
			</td>
			<td>on request (2-3 digit million range)</td>
		</tr>
	</tbody>
</table>

&nbsp;

<table border="0" cellpadding="0" cellspacing="2" style="font-family:arial">
	<tbody>
		<tr>
			<td colspan="2">
			4. Branded Vaccine to treat Viral Infections
			</td>
		</tr>
		<tr>
			<td colspan="2">&nbsp;</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Therapeutic Area:
			</td>
			<td>Viral Infections</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Products:&nbsp;
			</td>
			<td>Rx-Brand, patent-protected</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Territory:
			</td>
			<td>global</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Deal Type:
			</td>
			<td>Divestment</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Sales:
			</td>
			<td>&lt; 300 million EUR</td>
		</tr>
	</tbody>
</table>

&nbsp;

<table border="0" cellpadding="0" cellspacing="2" style="font-family:arial">
	<tbody>
		<tr>
			<td colspan="2">
			5. Rx-Brand to treat Hypertension
			</td>
		</tr>
		<tr>
			<td colspan="2">&nbsp;</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Therapeutic Area:
			</td>
			<td>Arterial Hypertension</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Products:&nbsp;
			</td>
			<td>Established Rx-Brand</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Territory:
			</td>
			<td>Europe</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Deal Type:
			</td>
			<td>Divestment</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Sales:
			</td>
			<td>&lt; 30 m EUR</td>
		</tr>
	</tbody>
</table>

&nbsp;

<table border="0" cellpadding="0" cellspacing="2" style="font-family:arial">
	<tbody>
		<tr>
			<td colspan="2">
			6. Small Rx Brands in Cardiovascular Diseases
			</td>
		</tr>
		<tr>
			<td colspan="2">
			&nbsp;
			</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Therapeutic Area:
			</td>
			<td>Cardiovascular System</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Products:&nbsp;
			</td>
			<td>Rx-Brands</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Territory:
			</td>
			<td>Hungary</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Deal Type:
			</td>
			<td>Divestment</td>
		</tr>
		<tr>
			<td style="white-space:nowrap">
			Sales:
			</td>
			<td>~ 1.2 m EUR</td>
		</tr>
	</tbody>
</table>

among many others...

If you are currently&nbsp;seeking to acquire any businesses in Pharma &amp; Healthcare we may assist you to find suitable targets.

We will provide you on the basis of an existing business relationship immediatly with confidential information on the businesses of interest. If no business relationship exists up to now we would have to conclude first a standard commission agreement (buy-side mandate) allowing us to exchange further details.

If you desire to divest any businesses or non-core assets we may support you efficetively to identify suitable buyers and to manage the entire sales process until successful closure of the transaction. We built up a proven network of business relations to strategic and financial investors worldwide over the past 20 years enabling us to assist you accordingly.

Looking&nbsp;forward to hearing from you.&nbsp;

Mit bestem Dank und freundlichen Gr&uuml;&szlig;en aus Zug 
Many thanks and best regards from Zug in Switzerland&nbsp;

Marc Raber

Dr. M. Raber 
Managing Director/Gesch&auml;ftsf&uuml;hrer

NB:&nbsp;Information on Corporate Sales, Brand Sales, Partnering Opportunities and Registrations &amp; Files&nbsp;you may find on our website.&nbsp;Register there for free (if not already done), enter the M&amp;A Database and search&nbsp;it for&nbsp;business opportunities. Detailed information on interesting businesses you may request directly through the database.

PMC Pharma Management Consultants GmbH 
Alisbachweg 22c 
CH-6315 Oberaegeri (Zug) 
Switzerland

<table border="0" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>Phone:</td>
			<td>+41 (0) 41 720 20 22&nbsp;</td>
		</tr>
		<tr>
			<td>Fax:</td>
			<td>+41 (0) 41 720 20 23&nbsp;</td>
		</tr>
		<tr>
			<td>Mobile:</td>
			<td>+41 (0) 79 358 21 86</td>
		</tr>
		<tr>
			<td>Web:</td>
			<td><a href="*link_url*">www.licensing4pharma.com</a></td>
		</tr>
		<tr>
			<td>Email:</td>
			<td><a href="mailto:info@licensing4pharma.com">info@licensing4pharma.com</a></td>
		</tr>
	</tbody>
</table>

&nbsp;

This e-mail was sent to info@worldwide.saraya.com !<img id='_x0000_i1024' src='http://www.licensing4pharma.com/images/button_pen.gif' style='height:22px; width:23px' />&nbsp;<a href='https://www.licensing4pharma.com/pmcfiles/app/index_confirmed.php?tk=cUZOaXoyWEdwUGdlek8yaldWYVdkenYzNXVyd1drem9xaEVaYWNIU1pRdz0='>Review and update</a> your settings (to provide you with suitable M&A opportunities you are looking for) or <a href='https://www.licensing4pharma.com/unsubscribe.php?url=YmM5NzE='> unsubscribe instantly</a>
</body></html>

--b1_68f22e579469b2a097885c44f9ac7b51--